CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • È«¿µ±Ç
  • ±³À°¼ö·ÃºÎÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ¼Ò¾Æ/Àü¸³¼±/¹è´¢/°á¼®/³²¼º
  • Á÷ À§: ±³¼ö(±³À°¼ö·ÃºÎÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
22 (±¹³»)±âŸ ½Å¼¼Æ÷¾ÏÀÇ ÀÚ°¡ µ¿Á¾ Á¾¾ç¼¼Æ÷ ¹× µ¿Á¾ ¶Ç´Â °ø¿©ÀÚ ¼öÁö»ó¼¼Æ÷ È¥ÇÕ¹é½ÅÀÇ °³¹ß ¹× Àû¿ë
21 (±¹³»)±âŸ ±Þ¼º½Å¿ì½Å¿° ȯÀÚÀÇ ´Ù±â°ü Ư¼ººñ±³
20 (±¹³»)±âŸ Pneumatic Lithotriptor¸¦ ÀÌ¿ëÇÑ ¿ä°ü°æÇÏ ¹è¼®¼ú: 274·Ê ºÐ¼®
19 (±¹³»)SCIE Evaluation of Short Term Clinical Effects and Presumptive Mechanism of Botulinum Toxin Type A as a Treatment Modality of Benign Prostatic Hyperplasia
18 (±¹³»)±âŸ Chlormadinone Acetate°¡ Àü¸³¼±ºñ´ëÁõ ȯÀÚÀÇ Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿øÄ¡¿¡ ¹ÌÄ¡´Â ¿µÇâ
17 (±¹³»)KCI ¹Úµ¿¼ö, ¿Àµµ¿¬, °­¸í¼­, ¾ÈÈñÁ¤, À̼±ÁÖ, ±è³²±Ù: ÀüÀ̼º ½Å¼¼Æ÷¾ÏÀÇ º¸Á¶ ¸é¿ªÄ¡·á·Î½á ÀÚ°¡Á¾¾ç¹é½ÅÀÇ Àû¿ë
16 (±¹³»)SCOPUS ÇϺοä·ÎÁõ»óÀ» º¸ÀÌ´Â Àü¸³¼±ºñ´ëÁõ¿¡¼­ Àü¸³¼± ³» Botulinum Toxin Type A (BTA) ÁÖÀÔ¿ä¹ýÀÇ Ãʱâ°æÇè°ú °æ¿äµµÀû Àü¸³¼±ÀýÁ¦¼ú°úÀÇ ´Ü±âÈ¿°ú ºñ±³
15 (±¹³»)SCOPUS Ãæ¼öµ¹±â¸¦ ÀÌ¿ëÇÑ Èĺ¹¸·°­ ºÎ½Å°æÀýÁ¾¿¡ ÀÇÇÑ ¿ä°ü °á¼ÕÀÇ ´ëÄ¡
14 (±¹³»)SCOPUS Àü¸³¼± »ý°ËÀ» ¿äÇϴ ȯÀÚ¿¡¼­ Àü¸³¼±¾Ï ¿¹Ãø Åë°è ¸ðµ¨ÀÇ °³¹ß
13 (±¹¿Ü)SCI Expanded PolytetrafluoroethyleneÀ» ÀÌ¿ëÇÑ ½Å¿øº¸Á¸ ¼ö¼ú
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 18 19 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729